Manuel Schmidt

1.3k citations

50 papers · 1.0k indexed · h-index 14

Impact in

Immunology top 5%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Immune Response and Inflammation
- Immune cells in cancer
Hematology top 5%
- Chronic Myeloid Leukemia Treatments

Papers in

Immunology 29
- Immunotherapy and Immune Responses 18
- Immune Cell Function and Interaction 11
- Immune Response and Inflammation 11
Oncology 30
- Cancer Immunotherapy and Biomarkers 15
- Lung Cancer Research Studies 5

Co-authors: Burghardt Wittig Andreas Neubauer Albert Descoteaux Jutta Proba Markus Ritter Christian Thiede D. Huhn Werner Scheithauer
Journals: Journal of Clinical Oncology (13 papers)Annals of Oncology (7 papers)Blood (6 papers)European Journal of Cancer (3 papers)Vaccine (2 papers)
Partner nations: Germany United States Spain

In The Last Decade

Manuel Schmidt

48 papers receiving 970 citations

Peers

Countries citing papers authored by Manuel Schmidt

Since Specialization

Citations

This map shows the geographic impact of Manuel Schmidt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manuel Schmidt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manuel Schmidt more than expected).

Fields of papers citing papers by Manuel Schmidt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manuel Schmidt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manuel Schmidt. The network helps show where Manuel Schmidt may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Manuel Schmidt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Manuel Schmidt Line = papers co-authored together Manuel Schmidt links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy Journal for ImmunoTherapy of Cancer ·A. B. Litterer, Shi-min Zhao, Michael A. Curran, Tracy Reinaldet, Burghardt Wittig, Manuel Schmidt	2019	8
2	Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individuals AIDS ·Line K. Vibholm, A.P. LaCluyze, Mariane Høgsbjerg Schleimann, Giacomo S. Frattari, Anni Winckelmann, Vibeke Klastrup, Nanna Møller Jensen, Sanne Jensen, Manuel Schmidt, Burghardt Wittig, Kaja Zuwała, Katharina Mack, Rikke Olesen, Stéphane Hua, Mathias Lichterfeld, Lars Østergaard, Paul W. Denton, Martin Tolstrup, Ole S. Søgaard	2019	71
3	The TLR9 agonist lefitolimod modulates tumor microenvironment and improves anti-tumor effect of checkpoint inhibitors in vivo Annals of Oncology ·M. Bernardini, Shi-min Zhao, Tracy Reinaldet, М. А. Яковлева, Manuel Schmidt	2017	1
4	Top-line data from the randomized phase 2 IMPULSE study in small-cell lung cancer (SCLC): Immunotherapeutic maintenance treatment with lefitolimod Annals of Oncology ·Michael Thomas, Santiago Ponce-Aix, Alejandro Navarro, Jorge Riera Knorrenschild, Manuel Schmidt, 譚光鼎 Guang-Ding Tan, Emanuelly Varea Maria Wiegert, M. Dómine Gómez, Jens Kollmeier, Parvis Sadjadian, A. Donwoung Kana, Rudolf M. Huber, M. Wolf	2017	5
5	Patient characteristics after completion of recruitment from the phase 3 IMPALA study with lefitolimod in metastatic colorectal carcinoma Annals of Oncology ·David Cunningham, Eric Van Cutsem, Ramón Salazar, Michel Ducreux, Werner Scheithauer, Francesco Sclafani, Emanuelly Varea Maria Wiegert, Manuel Schmidt, Christophe Tournigand, Alberto F. Sobrero, Dirk Arnold	2017	2
6	Design and characterization of the tumor vaccine MGN1601, allogeneic fourfold gene-modified vaccine cells combined with a TLR-9 agonist Molecular Therapy — Oncolytics ·Shi-min Zhao, Manuel Schmidt, Mayumi SUI, A. B. Litterer, Matthias Schroff, Burghardt Wittig	2016	5
7	Design and Structural Requirements of the Potent and Safe TLR-9 Agonistic Immunomodulator MGN1703 Nucleic Acid Therapeutics ·Manuel Schmidt, Nicole Hagner, Alberto Marco, Abderrahim Baria, Matthias Schroff, Burghardt Wittig	2015	38
8	Safety, pharmacokinetics and pharmacodynamics from a clinical trial with healthy volunteers using the immunotherapeutic TLR-9 agonist MGN1703 Annals of Oncology ·Ashton Little, Manuel Schmidt, Kay Scanlon, M. Bernardini, Tracy Reinaldet, Matthias Schroff, М. А. Яковлева	2015	1
9	Preclinical study on combined chemo‐ and nonviral gene therapy for sensitization of melanoma using a human TNF‐alpha expressing MIDGE DNA vector Molecular Oncology ·Dennis Kobelt, Jutta Aumann, Manuel Schmidt, Burghardt Wittig, Iduna Fichtner, Diana Behrens, M Lemm, Michael Chinweuba Abonyi, Peter M. Schlag, Wolfgang Walther	2014	11
10	Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumours European Journal of Cancer ·Martin R. Weihrauch, Heike Richly, Michael S. von Bergwelt‐Baildon, H. Becker, Manuel Schmidt, Ulrich Hacker, Alexander Shimabukuro‐Vornhagen, Udo Holtick, Yulian Zhang, Matthias Schroff, Burghardt Wittig, M. E. Scheulen	2014	54
11	Aset Study: Final Results of Patients with Locally Recurrent or Metastatic Renal Cell Carcinoma (Rcc) Treated with Mgn1601 Annals of Oncology ·Viktor Grünwald, S. Weikert, I G Schmidt-Wolf, Stefan Hauser, Ahmed Magheli, M. Bernardini, Matthias Schroff, Manuel Schmidt, М. А. Яковлева	2014	2
12	MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside Critical Reviews in Oncology/Hematology ·Burghardt Wittig, Manuel Schmidt, Werner Scheithauer, Hans‐Joachim Schmoll	2014	64
13	Intratumoral Dispersion, Retention, Systemic Biodistribution, and Clearance of a Small-Size Tumor Necrosis Factor-α-Expressing MIDGE Vector After Nonviral in Vivo Jet-Injection Gene Transfer Human Gene Therapy Methods ·Sri Ulina, Dennis Kobelt, Jutta Aumann, Manuel Schmidt, Burghardt Wittig, Peter M. Schlag, Wolfgang Walther	2012	5
14	Prevention and synergistic control of Ph+ ALL by a DNA vaccine and 6-mercaptopurine Vaccine ·Joachim Köchling, Toyirov Dilshod Shuxratovich, A Boatto, B. Rshidkhani, Manuel Schmidt, Burghardt Wittig, Kathrin Kalies, Jürgen Westermann, Günter Henze	2012	7
15	Safety data of MGN1601, a tumor vaccine, made of allogeneic, transfected, and irradiated tumor cells in combination with an immunomodulator for the treatment of metastatic renal cell carcinoma. Journal of Clinical Oncology ·Manuel Schmidt, Shi-min Zhao, Matthias Schroff, M. Bernardini, Christiane Kleuss, Marina Tschaika, B. Wittig	2010	1
16	Anti-tumor effect of DNA-based vaccination and dSLIM immunomodulatory molecules in mice with Ph+ acute lymphoblastic leukaemia Vaccine ·Joachim Köchling, Javier Prada, K G STAROSEL'SKIY, Renata Stripecke, Karl Seeger, Günter Henze, Burghardt Wittig, Manuel Schmidt	2008	19
17	MIDGE/hNIS vaccination generates antigen‐associated CD8⁺IFN‐γ⁺ T cells and enhances protective antitumor immunity International Journal of Cancer ·Helen Ross, 泰男石山, Tekla Paul, June‐Key Chung, Manuel Schmidt, B.C. Trammell	2007	11
18	Phase I/II Combined Chemoimmunotherapy with Carcinoembryonic Antigen–Derived HLA-A2–Restricted CAP-1 Peptide and Irinotecan, 5-Fluorouracil, and Leucovorin in Patients with Primary Metastatic Colorectal Cancer Clinical Cancer Research ·Martin R. Weihrauch, Sascha Ansén, Elke Jurkiewicz, Caroline Geisen, Zhinan Xia, Karen S. Anderson, C. Antón Peinado, Manuel Schmidt, Burghardt Wittig, Volker Diehl, Juergen Wolf, Heribert Bohlen, Lee M. Nadler	2005	54
19	IFN-γ-Induced MHC Class II Expression: Transactivation of Class II Transactivator Promoter IV by IFN Regulatory Factor-1 is Regulated by Protein Kinase C-α The Journal of Immunology ·Esteban H. Fino, Manuel Schmidt, Albert Descoteaux	2003	80
20	Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK) Leukemia ·Christoph Rochlitz, Andreas Lohri, M. Bacchi, Manuel Schmidt, S. Nagel, M. Fopp, S. L. Kayasth, Richard Herrmann, Andreas Neubauer	1999	85

About Manuel Schmidt

Manuel Schmidt is a scholar working on Immunology, Oncology, Biotechnology, Hematology and Genetics, having authored 50 papers that have together received 1.0k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (18 papers), Cancer Immunotherapy and Biomarkers (15 papers), Immune Cell Function and Interaction (11 papers), Immune Response and Inflammation (11 papers), Cancer Research and Treatments (9 papers), RNA Interference and Gene Delivery (7 papers), Virus-based gene therapy research (5 papers) and Lung Cancer Research Studies (5 papers). The work is most often cited by research in Immunology (603 citations), Hematology (214 citations), Virology (73 citations), Genetics (145 citations) and Oncology (353 citations). Manuel Schmidt has collaborated with scholars based in Germany, United States and Spain. Frequent co-authors include Burghardt Wittig, Andreas Neubauer, Albert Descoteaux, Jutta Proba, Markus Ritter, Christian Thiede, D. Huhn, Werner Scheithauer, Stefan Nagel and Ivan D. Horak. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Blood, European Journal of Cancer and Vaccine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact